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Background. Considerable efforts have been made to better understand the effectiveness of large-scale preventive chemother-
apy therapy for the control of morbidity caused by infection with soil-transmitted helminths (STHs): Ascaris lumbricoides, Trichuris 
trichiura, and the 2 hookworm species, Necator americanus and Ancylostoma duodenale. Current World Health Organization 
(WHO) guidelines for STH control include mass drug administration (MDA) programs based on prevalence measurements, aiming 
at reducing morbidity in pre–school-aged children (pre-SAC) and school-aged children (SAC) by lowering the prevalence of mod-
erate- to heavy-intensity infections to <1%.
Methods. We project the likely impact of following the current WHO guidelines and assess whether the WHO morbidity goals 
will be achieved across a range of transmission settings. We also investigate modifications that could be made to the current WHO 
treatment guidelines, and project their potential impacts in achieving morbidity and transmission control.
Results. While the standard guidelines are sufficient at low transmission levels, community-wide treatment (ie, involving pre-
SAC, SAC, and adults) is essential if WHO morbidity goals are to be met in moderate- to high-transmission settings. Moreover, 
removing the recommendation of decreasing the treatment frequency at midline (5–6 years after the start of MDA) further improves 
the likelihood of achieving morbidity control in SAC.
Conclusions. We meld analyses based on 2 mathematical models of parasite transmission and control by MDA for the domin-
ant STH species, to generate a unified treatment approach applicable across all settings, regardless of which STH infection is most 
common. We recommend clearly defined changes to the current WHO guidelines.
Keywords. soil-transmitted helminths; control; WHO guidelines; mass drug administration; mathematical modelling.
The London Declaration on Neglected Tropical Diseases 
(NTDs), launched in 2012, has helped to highlight the impor-
tance of a wide range of infections, including the soil-transmit-
ted helminths (STHs), which are endemic in many developing 
countries [1]. These intestinal nematode parasites, namely the 
roundworm Ascaris lumbricoides, the hookworms Ancylostoma 
duodenale and Necator americanus, and the whipworm 
Trichuris trichiura are the cause of considerable morbidity 
[2, 3]. The Global Burden of Diseases, Injuries, and Risk Factors 
Study 2016 places the prevalence of infection with STHs overall 
at 1.5 billion cases globally, with around 800 million cases of 
ascariasis and well in excess of 400 million each of trichuriasis 
and hookworm disease [4]. Individuals become infected with 
Ascaris and Trichuris when they ingest parasitic eggs released 
into the environment through the feces of infected individu-
als. Hookworm eggs mature and hatch in the soil, and become 
larvae, which penetrate through human skin when individuals 
walk barefoot in contaminated habitats. The severity of mor-
bidity is correlated to the intensity of infection. Moderate- to 
high-intensity infections are linked to diarrhea, anemia, malnu-
trition, and physical and cognitive impairments [5, 6]; Ascaris 
and Trichuris are most commonly found in school-aged chil-
dren (SAC) [7], whereas for hookworm the highest worm bur-
dens are typically found in adults [8].
The World Health Organization (WHO) has provided guide-
lines on large-scale preventive chemotherapy through programs 
employing mass drug administration (MDA) of the drugs 
albendazole or mebendazole. The guidelines aim to reduce 
morbidity from STH infections in pre–school-aged children 
(pre-SAC) and SAC by reducing the prevalence of moderate- or 
heavy-intensity infections to <1% in SAC [9], the thresholds for 
which are parasite-specific and based on fecal egg counts [1]. 
The WHO recommends scaling up MDA programs to target at 
least 75% of SAC, and to include individuals who are at risk 
for morbidity caused by STH infections (ie, pregnant women 
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in the last 2 semesters of pregnancy, lactating women, or adults 
in high-risk occupations) [3]. Regular treatment is required as 
eggs or larvae remaining present in the environment for many 
months can be the cause of reinfection.
Over the past several years, members of the NTD Modelling 
Consortium have published papers on mathematical models of 
the transmission dynamics, control, and elimination of STH 
[8, 10–18]. In this study, we expand on this work through the 
application of two mathematical models, which differ in struc-
ture, developed by Imperial College London (ICL) and Erasmus 
Medical Center Rotterdam (EMC). We focus on predicting the 
extent to which the current WHO guidelines for starting, scal-
ing up, and stopping MDA against STHs succeed in meeting the 
stated morbidity goals, the circumstances under which they fail, 
and what changes could be made to the guidelines to increase 
the likelihood of reaching the WHO-defined morbidity goals.
METHODS
General Modeling Approach
Individual-based stochastic transmission models, developed 
independently by ICL and EMC, were used in this study in which 
changes in the worm burden of all individuals within a defined 
human host population were simulated over time and across host 
age classes. Both models assume a high level of aggregation in 
worm burdens, that is, many individuals have a few worms, and 
a few individuals have many worms. Birth and death rates were 
chosen to generate an age distribution typical of sub-Saharan 
African countries. The acquisition and death of worms are sto-
chastic, with species-specific mean lifespans. Exposure and con-
tribution of the worms to the infective pool in the human habitat 
are age specific. Both models assume that the worms are polyg-
amous; the EMC model also simulates a prepatent period and 
insemination of female worms. Assessment of infection levels is 
made through a diagnostic submodel describing the Kato-Katz 
egg counting method. Details of the ICL and EMC model struc-
tures have been published previously [12, 13, 14, 15, 19].
We assume treatment with albendazole alone unless other-
wise stated. An individual’s treatment results in killing each par-
asite with a probability of 99% (Ascaris), 94% (hookworm), or 
60% (Trichuris, by default, see also below) in line with measured 
egg reduction rates [20–23]. Each independent village’s param-
eters are based on field data, fitted to the age-specific prevalence 
of infection profiles in a specific region. For each simulation, we 
evaluated whether a weighted mean prevalence of moderate to 
heavy infection in SAC 10 years after the start of MDA was <1%.
See the Supplementary Data for further details of parame-
terization, weighting methodology, and the models’ approaches 
toward describing worm fecundity. See Supplementary Table 1 
for moderate to heavy infection intensity thresholds.
Current WHO Guidelines
We simulate the impact of the current WHO guidelines 
(Figure  1), assuming 75% coverage of SAC [1]. Persistent 
Figure 1. World Health Organization (WHO) decision tree showing the current WHO guidelines to achieve morbidity control in school-aged children (SAC) using 75% cover-
age in SAC (black and orange boxes). The blue boxes represent the modified guidelines assuming 75% community-wide coverage (pre-SAC, SAC, and adults) to replace the 
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nonadherence was included within the models, which accounts 
for individuals not taking treatment at any round of MDA [14]. 
The decision to initiate, continue, or stop MDA within each 
simulation was based on the measured prevalence in SAC at 
baseline (before the start for MDA) and midline (5 years after 
the start of MDA). In both models, prevalences in age group-
ings (pre-SAC, SAC, and adults, as measured by eggs per gram 
of feces) vary between simulations due to stochastic effects act-
ing on human and worm demography, and sampling error in 
diagnostic testing, for which we assume that a single Kato-Katz 
smear of 41.7 mg is performed [9]. We assume that only SAC 
are tested to make treatment decisions, even where adults are 
treated, to allow for continuation of WHO-recommended prac-
tices regarding testing programs.
Modified Guidelines
For simulations where the WHO goal has not been achieved, we 
explored alternative strategies, such as disregarding the option 
of reducing the frequency of MDA after the midline evaluation 
(Figure 1). The options of stopping treatment if the measured 
prevalence is <1% and increasing treatment frequency at mid-
line are retained. The baseline decisions with regard to MDA 
frequency were kept the same as in the current WHO guide-
lines. In addition, the following modifications were considered: 
(1) MDA targeting SAC at 90% coverage rather than 75%; (2) 
expanded community-wide MDA at 25%, 50%, or 75% cover-
age for adults and pre-SAC (in addition to 75% coverage of 
SAC); and (3) use the drug combination ivermectin and alben-
dazole (rather than albendazole alone) in treating Trichuris 
to increase the effectiveness of treatment. We assumed an 
increased Trichuris worm kill rate per treatment of 95%, when 
coadministration was applied, instead of 60% [24].
RESULTS
As infection in each of the simulated villages changes over 
time, prevalence-based treatment decisions are made per vil-
lage consistent with the decisions laid out in Figure 1. Ten years 
after the start of MDA, a simulated Kato-Katz measurement is 
taken of moderate to heavy infection rates. The mean of vil-
lages’ rates in each category of possible decisions is shown in 
Figures 2 and 3, color-coded by whether the WHO morbidity 
goal is met.
Figure 2 reveals that for both annual and biannual baseline 
treatment, the current WHO guidelines are more successful at 
achieving the morbidity goal if the midline (5–6 years after the 
start of MDA) medium-heavy prevalence is low. When hook-
worm and Trichuris midline prevalences are <10%, the current 
WHO guidelines almost always take the prevalence of moderate 
to heavy infections in SAC to <1%, according to both models. In 
contrast, both models identify that in scenarios in which prev-
alence is >50% at baseline and remains so at the midline, twice-
yearly followed by thrice-yearly treatment is unable to control 
transmission for any of the STH species.
In contrast, both models predict a substantial improvement 
in morbidity outcomes with community-wide treatment, with 
the WHO morbidity goal being met in most settings (Figure 3). 
The primary exception is high-transmission hookworm set-
tings, in which outcomes are more mixed. Model predictions 
differ on whether the goal will be achieved where baseline prev-
alence exceeds 50%. No villages in the EMC model remained 
above 50% infection prevalence at the midline evaluation; 
however, results from the ICL model suggest that those that do 
(representing areas particularly resilient to treatment) will fail 
to meet the morbidity target, despite the much broader com-
munity-wide coverage.
Figure 2. Prevalence of moderate to heavy soil-based helminth infection in school-aged children (SAC) after 10 years of treatment under current guidelines assuming 
75% coverage in SAC, highlighted by achievement (green) or otherwise (red) of 1% prevalence goal, or varying predictions between models (yellow), in various transmission 
settings. Results in each cell have Imperial College London results at the top and Erasmus Medical Center Rotterdam below. Figures in parentheses are the probability of 
measuring a prevalence of medium- and high-intensity infections <1% from a sample of all SAC. Decisions are based on measured prevalence of infection and correspond 
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Figure 2 shows some differences in the predictions of the 
2 models to treatment interventions. The descending rows, in 
each column, show results from villages of increasing prev-
alence at the midline decision point. Generally, for villages 
with a low transmission intensity (and so low prevalence 
at midline), the ICL model shows a lower endline preva-
lence than the EMC model. For villages with high transmis-
sion intensity, the EMC model generally shows the greater 
response to treatment. These differences reflect the different 
modeling approaches to impact of individual worm load on 
egg production. Given identical age-specific levels of infec-
tion, adults contribute more to transmission in the EMC 
model than in the ICL model because of different assump-
tions about age patterns in the practice of open defecation 
(see Supplementary Data). As such, the EMC model predicts 
a larger benefit of community-wide treatment (Figure  3 vs 
Figure 2) over targeted deworming of SAC compared to the 
ICL model.
It is important to consider the effect of uncertainty generated 
by the stochastic nature of the processes being modeled as the 
endline prevalence results quoted in Figures 2 and 3 are mean 
values. Prediction intervals for model prevalence estimates are 
provided in Supplementary Table 2.
The differences between models notwithstanding, our results 
indicate that current guidelines can produce good outcomes in 
SAC morbidity control in low-prevalence (and perhaps some 
moderate-prevalence) areas (Figure  2). However, in high-
er-prevalence areas, adult infection may be enough to sustain 
high reinfection of SAC and put achievement of the morbidity 
goal at risk. In those areas, community-wide transmission is 
beneficial. In many cases, sufficient community-wide treatment 
can be expected to break transmission, with obvious benefits for 
long-term morbidity control.
Both models predict improvement in Trichuris outcomes 
when both albendazole and ivermectin are administered, rather 
than albendazole only. Applying community-wide treatment 
has a greater impact on morbidity compared with the drug 
coadministration strategy (Supplementary Figure 1).
DISCUSSION
Using two different mathematical models of STH transmis-
sion and control, we have investigated the impact of the cur-
rent WHO guidelines on the likelihood of achieving the STH 
morbidity goals in SAC. In cases where the morbidity goals are 
not achieved, we propose modifications of these guidelines as 
summarized in Table 1.
Figure 3. Prevalence of moderate to heavy soil-transmitted helminth infection in school-aged children (SAC) after 10 years of treatment, under recommended updates to 
treatment guidelines of 75% community-wide coverage. Results in each cell have Imperial College London (ICL) results at the top and Erasmus University Medical Center 
(EMC) below. Figures in parentheses are the probability of measuring a prevalence of medium- and high-intensity infections <1% from a sample of all SAC. Highlighted by 
achievement (green) or otherwise (red) of 1% prevalence goal, or varying predictions between models (yellow), in various transmission settings. Results in each cell have ICL 
results at the top and EMC below. Figures in brackets are the probability of measuring a prevalence of medium- and high-intensity infections <1% from a sample of all SAC. 
Decisions are based on measured prevalence of infection and correspond with World Health Organization recommendations [1]. The gray box indicates that no villages fell 
into those categories in either EMC or ICL models. Abbreviation: MDA, mass drug administration.
Table 1. Summary of Success or Failure to Meet World Health Organization Morbidity Goal of <1% Prevalence of Moderate- to Heavy-Intensity Infections 
in School-Aged Children
Current Guidelines Recommended Updates
There is a high likelihood of failing to achieve the WHO morbidity goals as the baseline 
prevalence increases. Options where the treatment frequency is reduced at midline 
are unlikely to reach the morbidity goals. In general, if prevalence of infection remains 
high (≥20%) at the midline evaluation, models predict that MDA will fail to achieve the 
morbidity goal. Prevalence of infection <20% at midline indicates achievement of the 
goal in some circumstances.
We recommend providing 75% community-wide coverage while 
removing the option to reduce the treatment frequency. In areas 
where Trichuris is dominant, coadministration of albendazole and iver-
mectin would also be beneficial.
Prevalence of infection refers to measurements in school-aged children. Recommended updates are as follows: 75% community-wide treatment and no reduction in treatment frequency 
(unless prevalence falls below 1%, treatment may be stopped; follow-up assessments recommended). See also Figure 1 for prevalence-based treatment decisions.
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Current WHO treatment guidelines recommend ending MDA 
if infection prevalence has been reduced to <1% after 5–6 years of 
treatment. Our analyses suggest that a 1% prevalence threshold 
is not always a good criterion on which to judge whether or not 
to cease treatment. We have accounted for the poor sensitivity 
of Kato-Katz diagnostics at low prevalence, but poor accessibil-
ity of individuals or groups may hide infection from surveillance, 
something the models do not account for at present.
Updated guidelines for STH MDA have recently been made 
public [25]. The new guidelines do not include explicit rec-
ommendations that treatment frequency be reduced at mid-
line evaluation. This is in line with our findings. In addition, 
the guidelines make explicit that women of childbearing age 
should be treated, except those in the first trimester of preg-
nancy. While a step in the right direction, our findings suggest 
that coverage short of the entire community at a level of 75% is 
unlikely to result in achievement of the morbidity goals in SAC, 
particularly in higher-prevalence areas.
The same guideline updates change the overall prevalence 
threshold in WHO treatment guidelines for discontinuing 
MDA from 1% to 2%. Pragmatic concerns regarding the diffi-
culty of measuring prevalence <1% must be taken into account; 
nevertheless, if such a threshold is to be useful, it must be based 
on sound evidence. Recent work has shown progress in deter-
mining appropriate infection thresholds for the purpose of 
measuring true interruption of STH transmission [26, 27].
Moreover, our results show that discontinuing MDA on the 
basis of having achieved even a 1% prevalence threshold may be 
premature in most high-transmission settings, and ineffective 
in achieving the stated control aims without careful follow-up 
evaluation. Though the measured prevalence of infection in 
SAC may be low, stopping treatment may nevertheless lead to 
reoccurrence of transmission and “bounce back” to pretreat-
ment levels of infection in part due to the reservoir of infection 
in adults. We recommend that if MDA is stopped, rigorous sur-
veillance remain in place to prevent morbidity associated with 
STH infection returning.
A bounce-back of infection after cessation of MDA may pro-
vide a window for a subpopulation of parasites that is (partially) 
treatment resistant on the brink of extinction to reconstitute. 
To what extent and how fast preventive chemotherapy leads to 
anthelminthic resistance in STH is uncertain at present, but it 
is an active area of research. It is of obvious relevance given the 
observation of widespread drug resistance in helminth species 
infecting small ruminants and cattle, which are also controlled 
by means of mass chemoprophylaxis [28, 29]. As in veterinary 
medicine, development of resistance is probably best delayed by 
the use of multiple drug combinations and reductions in envir-
onmental contamination and/or exposure (ie, improved access 
to water, hygiene, and sanitation).
The current WHO guidelines do not explicitly recommend 
follow-up for STH infection detection after cessation of MDA 
once the morbidity goals have been reached [1]. Parallel WHO 
guidelines for treatment of schistosomiasis do include a recom-
mendation for serology to be carried out if prevalence <1% in 
SAC following 5–6 years of treatment [1, 30]. Though there are 
no commercially available serology tests available for STH, new, 
more sensitive diagnostic techniques are emerging [31]. We rec-
ommend that the new quantitative polymerase chain reaction 
diagnostic techniques to detect parasite DNA in feces be applied 
in some trial settings to help ascertain if low-intensity infections 
persist after MDA cessation. Serology tests may still give a posi-
tive outcome after the infection is cleared, as antibodies remain 
present for some time post-clearance (if not lifelong).
Given the potential for a reservoir of infection in adults if 
treatment remains SAC focused, surveillance of the entire 
population across all age groups via transmission assessment 
surveys is to be recommended. Hence, a key part of deciding 
whether community-wide MDA is appropriate should be an 
assessment of the level of infection in adults.
As parasite elimination is approached, issues related to reach-
ing the last few infected individuals come to the fore. This is 
an area of active research. Recent work on systematic noncom-
pliance with MDA treatment indicates that the importance of 
this factor to effective control by MDA varies between helminth 
species, with the longer-lived species perhaps most affected 
[14, 32]. The importance of accurate coverage data in informing 
policy is well understood [33]. However, surprisingly, few longi-
tudinal studies on compliance of individuals with anthelmintic 
treatment have been conducted. Such studies require individu-
als to be followed up over successive rounds of treatment, over 
a number of years. This poses considerable logistical challenges. 
The need for good MDA coverage data has driven the inclu-
sion of individual-level and longitudinal data collection in the 
DeWorm3 study [34, 35]. Though the 3 dominant STH species 
are treated collectively in terms of the drug used and the formu-
lation of the WHO treatment guidelines, differences are evident 
in required action to meet the WHO prevalence goal. Though 
we mirror current WHO guidelines in producing recommenda-
tions that are applicable across STH diseases as a whole, ideally 
the guidelines would reflect the locally dominant species and 
provide species-specific recommendations, as well as differ-
entiating by disease prevalence. In very low-prevalence areas 
(<10%), current guidelines may be sufficient. Less reliably, given 
the models’ mixed predictions, the goal may be achievable in 
areas largely free of hookworm with Ascaris or Trichuris preva-
lence up to 20%. In all other circumstances, we strongly recom-
mend community-wide treatment at high coverage. Regional 
circumstances and availability of data on prevalence of the dif-
ferent diseases will determine whether treating STH collectively 
or tailored by disease and local prevalence is the best approach. 
Where granular data are not available, we recommend commu-
nity-wide treatment. In addition, given the low drug efficacy 
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expect more aggressive, higher-coverage MDA to be necessary 
where mebendazole is used. In clearing Trichuris, a more spe-
cific set of guidelines may be needed given the higher efficacy 
of an albendazole + ivermectin drug coadministration regimen.
We have ensured that our models take account of geograph-
ical heterogeneity in transmission by systematically studying a 
range of parameter values, but have deliberately avoided repli-
cating transmission patterns in any particular region or coun-
try. A  number of factors will influence transmission patterns 
within and between specific localities, notably migration of 
infected individuals between villages or towns, perhaps season-
ally for work. This is not accounted for in the current versions 
of our models, in part because detailed data on such movements 
are limited to date. However, the availability of relevant data, 
based on mobile phone usage, is growing in many regions with 
endemic STH infection (eg, Kenya). Some published research 
has investigated the impact of human movement [26], but much 
remains to be explored.
Global efforts to eliminate the NTD lymphatic filariasis as a 
public health problem [36] provide an opportunity; the drug 
regimen used in MDA against lymphatic filariasis (LF)—a com-
bination of albendazole and either ivermectin or diethylcar-
bamazine, community-wide—is also effective against STH. As 
such, large-scale LF elimination efforts have greatly increased 
the number of people being treated for STH. As regional LF 
elimination programs move into transmission assessment sur-
veys to examine suitability for ending MDA, there is scope to 
coordinate LF surveillance with continued treatment for STH 
[35]. Missing this opportunity, or treating only children, risks 
recrudescence and the loss of gains already made against STH 
infection.
Expanded MDA programs can be considerably more cost-ef-
fective than treating smaller subpopulations when economies 
of scale and the low costs of the (often donated) relevant drugs 
are taken into account [8, 37]. Coordination between multiple 
interventions, such as with LF elimination programs, provides 
scope to reduce costs further.
CONCLUSIONS
Both modeling approaches agree that in most transmission set-
tings, the present guidelines for treatment coverage need to be 
broadened to include the treatment of all age groups, to achieve 
the WHO morbidity goals. Therefore, we recommend attempt-
ing to achieve 75% community-wide coverage, while removing 
the option of reducing the treatment frequency as prevalence 
drops during a long-term MDA program.
Though WHO goals on STH are focused on morbidity control 
rather than (as yet) elimination as such, there is obvious benefit 
to coordinated assessment and continued treatment to achieve 
more effective morbidity control, and perhaps mitigation of 
ongoing costs through interruption of parasite transmission.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding 
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